Cancer Research Programs
UCLA Trials at Cancer Care Associates
For questions please contact our UCLA research nurse,
Sherry at (310) 750-3376
Active Trials
The following clinical trials are available at Cancer Care Associates in coordination with the UCLA Division of Hematology/Oncology. All patients on these trials are treated in our infusion center in Redondo Beach. The following studies are subject to change and may not be continually or currently open. The studies are strictly voluntary and all experimental study drugs are provided at no charge to the patients. There are precise criteria for enrollment in these clinical trials because the researchers are attempting to answer a specific treatment question so that not all patients will be eligible to enroll.
Breast Cancer: TORI 11, BETH Trial. This study is for Her2 positive patients after initial breast surgery. All patients on this study will get standard treatment, Taxotere/Carboplatin/Herceptin. Some patients will be selected to also get Avastin. The purpose of this study is to see whether the addition of Avastin to the current best standard treatment will result in higher cure rates. Status OPEN.
Breast Cancer: TORI/TRIO B07 Trial. This study is for Her2 positive patients who get chemotherapy before initial breast surgery. All patients receive Taxotere/Carboplatin, a standard chemotherapy. They also get a Her2 targeting drug which is selected by computer, either Herceptin, or Tykerb, or both. The study requires additional biopsies for molecular analysis at UCLA. The purpose of the study is to test which is the superior targeting strategy against the Her2 protein. Status OPEN
Breast Cancer: TDM 4450 Genentech. This is a first line study for patients with metastatic Her2 positive breast cancer. No previous chemotherapy for metastatic disease is permitted. Patients receive either standard treatment with Taxotere/Herceptin or an experimental antibody which combines Herceptin with DMI (a chemotherapy) plus Taxotere. The purpose of the study is to see if this novel combination antibody is more effective than Herceptin. Patients who arent initially selected to receive the new antibody can get it later as part of this study. Status OPEN.
Breast Cancer: TRIO 17. This is for patients with metastatic breast cancer. Some previous chemotherapy is allowed. The experimental treatment is Panobinostat, which is a deacetylase inhibitor, a novel new treatment approach. This drug targets lysine groups which are important in tumor growth. Status OPEN.
Breast Cancer: Ribbon 1and 2. This is an international study testing the effectiveness of adding Avastin to standard chemotherapy in patients with metastatic breast cancer. This has been demonstrated to be an active combination in lung and colon cancer and the purpose of this study is to evaluate the combination in both the 1st line and 2nd line setting in advanced breast cancer. All patients receive the current best chemotherapy and then are selected by computer to receive Avastin, a monoclonal antibody that disrupts blood vessel formation by cancer tissue. Avastin is provided at no charge. Status FULLY ENROLLED.
Breast Cancer: BiPar Triple Negative Trail. This is a long awaited study of an experimental treatment for patients with metastatic triple negative breast cancer. Patients have breast cancers that are ER/PR/Her2 negative. All patients receive a standard chemotherapy with Gemzar/Carboplatin and some patients are selected to also get BSI-201. This drug is a small molecule inhibitor of a critical DNA repair enzyme. It is supposed to prevent tumor growth by disrupting genetic material. Status OPEN.
Esophagus/Stomach: GI-05. This is a first line treatment for patients with metastatic cancer of the esophagus or stomach. All patients receive FOLFOX (5FU, Leucovorin, Oxaloplatin), a standard chemotherapy. Some patients are selected to also get Tarceva, which is a pill that targets the protein EGFR. This protein is present on many cancer cells and is important in helping cancers to grow and spread. The purpose of the study is to try to improve upon standard chemotherapy by adding a targeting drug. Status OPEN.
Esophagus/Stomach: GSK/TRIO 13. This is a first line treatment for patients with adenocarcinoma of the esophagus or stomach that is metastatic or inoperable. The cancer needs to be Her2 postive. All patients receive CapeOX (Xeloda and Oxaloplatin), a standard chemotherapy. Some patients are selected to receive Tykerb, a pill that targets a number of proteins including Her2. The purpose of the study is to test whether the addition of a targeting drug will make the chemotherapy regimen more effective. Status OPEN.
Lung Cancer: CBP 8-02 CanBas Trial. This is a first line trial for patients with metastatic non-small cell lung cancer. All patients receive current best chemotherapy, Alimta/Carboplatin, and some patients are selected to also receive an experimental targeting drug, CBP501. The purpose of the study is to see if the addition of this novel agent will make the standard chemotherapy more effective. Status PENDING.
Lung Cancer: CASA, Novartis. This is a second line trial for patients with metastatic non-small cell lung cancer who have already received one type of chemotherapy and require more treatment. All patients receive a standard chemotherapy, Taxotere, and some are selected by computer to receive a targeting agent ASA404. ASA404 is a small molecule vascular disrupting agent and is supposed to damage the blood vessel network within cancers. Status OPEN.
Lung Cancer: Eli Lilly H3E. This is a 1st line study for patients with metastatic non-small cell lung cancer. The study is testing to see which is the best initial treatment and which is the best maintenance treatment. Patients are selected to get either Alimta/Carboplatin/Avastin followed by Alimta/Avastin or Taxol/Carboplatin/Avastin followed by Avastin. Both strategies are considered excellent and effective. Status OPEN.
Lymphoma: NHL Eli Lilly: Patients with high risk large B-cell lymphoma receive Rituxan/CHOP as standard treatment. On completion of chemotherapy, patients are selected to receive enzastaurin, a pill, for one year. Enzastaurin is a multi-kinase inhibitor and targets several proteins that promote the growth of large B-cell lymphoma. The purpose of the study is to test if remission can be maintained and cure rates improved with this experimental drug. Status OPEN.